Lenvatinib versus sorafenib in hepatocellular carcinoma | 合法藥品大搜索

由ADipasquale著作·2021·被引用1次—Lenvatinibversussorafenibinthefirst-linetreatmentofunresectablehepatocellularcarcinoma-newtherapeuticscenario.

1Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, 20090, Italy; 2IRCCS Humanitas Research Hospital, Rozzano, 20089, Italy

Correspondence: Armando SantoroIRCCS Humanitas Research Hospital, Via Manzoni 56, Rozzano, 20089, ItalyTel +39 28224 4080Fax +39 28224 4592Email [email protected][1]

Abstract: Hepatocellular carcinoma (HCC) is the fifth most common malignancy across the world. Alongside improvement in local approaches for early stages, the prognosis of patients with advanced disease remains poor. The tyrosine kinase inhibitor sorafenib was the first drug approved for advanced HCC. During the past decade, this has been extensively explored in real-life settings, such as Eastern Cooperative Oncology Group performance status 2, Child-Pugh B liver function, chronic kidney disease, HIV infection, transplant recipients and the elderly. After 10 years, the multikinase inhibitor lenvatinib was approved in first-line setting. The Phase III REFLECT trial...